Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 7;118(30):e2024302118. doi: 10.1073/pnas.2024302118

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 the Author(s). Published by PNAS.

This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

PMC Copyright notice

Fig. 4. — Analyses of drug combinations on anti–SARS-CoV-2 activity, cell viability, and their synergistic effects. Two-dimensional matrix of dose–response for relative viral inhibition: (A) omipalisib/remdesivir, (D) tipifarnib/omipalisib, and (G) tipifarnib/remdesivir. The heatmap depicts relative viral inhibition scaled to the range of 0 to 100%. Two-dimensional matrix of dose–response for relative cell viability: (B) omipalisib/remdesivir, (E) tipifarnib/omipalisib, and (H) tipifarnib/remdesivir. The heatmap depicts relative cell viability scaled to the range of 0 to 100%. Topographic two-dimensional map of synergy scores determined by synergyfinder using the data in A, D, and G, respectively: (C) omipalisib/remdesivir, (F) tipifarnib/omipalisib, and (I) tipifarnib/remdesivir. The synergy map highlights synergistic and antagonistic dose regions in red and green colors, respectively. A yellow box represents the area with the highest synergy score obtained by synergyfinder.